LJ-2698 (FM101) is an orally active adenosine A3 receptor ( Adenosine A3 Receptor ) antagonist . LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK , ERK , and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis ( apoptosis ) in mice . LJ-2698 induces mitochondrial dysfunction, necroptosis , and intrinsic apoptosis . LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Emphysema | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > NF-κB | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > PGC-1α | Products > Signaling Pathways > JNK | Products > Signaling Pathways > ERK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Necroptosis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Adenosine Receptor | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.